Symbols

ADCT

ADC Therapeutics·NYSE

--(--)

ADCT fundamentals

ADCT Q4 2025 Earnings

ADC Therapeutics (ADCT) released its earnings on Mar 10, 2026: revenue was 23.06M (YoY +36.36%), beat estimates; EPS was -0.04 (YoY +86.21%), beat estimates.

Revenue / YoY

23.06M

+36.36%

EPS / YoY

-0.04

+86.21%

Report date

Mar 10, 2026

ADCT Earnings Call Summary for Q4,2025

Strategic Focus on ZYNLONTA: 50% cost reduction and clinical trial progress (LOTIS-5, LOTIS-7) position ZYNLONTA for $600M-$1B peak U.S. revenue.
Q4 2025 Financials: $22.3M net product revenue, $261M cash runway, and 15% Y/Y operating expense reduction.
Key Catalysts: Q2 2026 LOTIS-5 PFS readout, Q4 2026 LOTIS-7 data, and 2027 regulatory filings for second-line DLBCL expansion.
Market Potential: 10% third-line DLBCL share ($100M) + second-line expansion ($200M-$300M) drive long-term growth.

Earnings

EPS

Revenue

Revenue & Expenses

ADCT has released its 2025 Q4 earnings report, with revenue of 23.06M, reflecting a YoY change of 36.36%, and net profit of -6.41M, showing a YoY change of 79.14%. The Sankey diagram below clearly presents ADCT's revenue sources and cost distribution.

Key Indicators

ADC Therapeutics (ADCT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

ADC Therapeutics (ADCT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

ADC Therapeutics (ADCT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

ADC Therapeutics (ADCT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown